Table 3.

Probability of survival and survival free from transformation to accelerated and blast phase at 36 months by best response. All patients (A) Overall and (B) By landmark analysis at 6 months, and only patients treated with 2^nd TKI (C) Overall and (D) By landmark analysis at 6 months.

(A)
Best response responses to TKI	Survival		Survival free from transformation
	%	95% C.I.	%	95% C.I.
CCyR	98	95-100	95	90-100
PCyR	83	65-100	73	47-100
MinCyR	86	72-100	84	69-100
CHR only	76	57-100	88	67-100
No response	71	56-90	0	NA

(B)
Overall responses	Survival		Survival free from transformation
	%	95% C.I.	%	95% C.I.
CCyR	98	94-100	95	90-100
PCyR	89	71-100	73	47-100
MinCyR	85	71-100	84	69-100
CHR only	72	52-100	88	67-100
No response	67	45-100	0	NA

(C)
Best response responses to TKI	Survival		Survival free from transformation
	%	95% C.I.	%	95% C.I.
CCyR	97	94-100	94	89-100
PCyR	88	67-100	63	32-100
MinCyR	90	78-100	88	75-100
CHR only	67	45-100	86	63-100
No response	67	47-95	0	NA

(D)
Overall responses	Survival		Survival free from transformation
	%	95% C.I.	%	95% C.I.
CCyR	97	94-100	94	89-100
PCyR	86	63-100	63	32-100
MinCyR	89	77-100	88	75-100
CHR only	64	41-100	86	63-100
No response	71	45-100	0	NA